TY - JOUR
T1 - Emerging role of biologics for the treatment of melioidosis and glanders
AU - Tapia, Daniel
AU - Sanchez-Villamil, Javier I.
AU - Torres, Alfredo G.
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/12/2
Y1 - 2019/12/2
N2 - Introduction: Two important pathogenic species within the genus Burkholderia, namely Burkholderia pseudomallei (Bpm) and Burkholderia mallei (Bm), are the causative agents of the life-threatening diseases melioidosis and glanders, respectively. Due to their high mortality rate and potential for aerosolization, they have gained interest as potential biothreat agents and are classified as Tier 1 Select Agents. Areas covered: The manuscript provides an overview of the literature covering the efforts taken in the last 10 years to develop new therapeutics measures against both Bpm and Bm, with attention on novel therapeutic agents. Expert Opinion: As a result of the complicated antibiotic regimens necessary to treat these infections, development of novel therapeutics is needed to treat both diseases. In recent years, the understanding of the pathogenesis of Burkholderia has improved significantly and so have the efforts to develop novel therapeutic agents with high efficacy, either alone, or in combination with conventional antibiotics.
AB - Introduction: Two important pathogenic species within the genus Burkholderia, namely Burkholderia pseudomallei (Bpm) and Burkholderia mallei (Bm), are the causative agents of the life-threatening diseases melioidosis and glanders, respectively. Due to their high mortality rate and potential for aerosolization, they have gained interest as potential biothreat agents and are classified as Tier 1 Select Agents. Areas covered: The manuscript provides an overview of the literature covering the efforts taken in the last 10 years to develop new therapeutics measures against both Bpm and Bm, with attention on novel therapeutic agents. Expert Opinion: As a result of the complicated antibiotic regimens necessary to treat these infections, development of novel therapeutics is needed to treat both diseases. In recent years, the understanding of the pathogenesis of Burkholderia has improved significantly and so have the efforts to develop novel therapeutic agents with high efficacy, either alone, or in combination with conventional antibiotics.
KW - Burkholderia mallei
KW - Burkholderia pseudomallei
KW - antibiotics
KW - antibodies
KW - glanders
KW - melioidosis
KW - phages
KW - therapeutics
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85074349379&partnerID=8YFLogxK
U2 - 10.1080/14712598.2019.1677602
DO - 10.1080/14712598.2019.1677602
M3 - Artículo de revisión
C2 - 31590578
AN - SCOPUS:85074349379
SN - 1471-2598
VL - 19
SP - 1319
EP - 1332
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 12
ER -